Teacher Retirement System of Texas Buys 9,896 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Teacher Retirement System of Texas raised its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 59.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,682 shares of the company's stock after buying an additional 9,896 shares during the quarter. Teacher Retirement System of Texas owned about 0.06% of Omnicell worth $1,188,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of OMCL. Smartleaf Asset Management LLC grew its position in Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares in the last quarter. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the period. First Horizon Advisors Inc. increased its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the last quarter. KBC Group NV raised its holdings in Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after buying an additional 778 shares during the period. Finally, AlphaQuest LLC lifted its position in Omnicell by 307.8% in the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company's stock worth $159,000 after buying an additional 2,699 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Omnicell Stock Up 0.6 %

Shares of OMCL stock traded up $0.20 during mid-day trading on Wednesday, hitting $35.46. The stock had a trading volume of 319,583 shares, compared to its average volume of 517,457. The firm has a market capitalization of $1.66 billion, a P/E ratio of 131.34, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The firm's 50-day moving average is $38.56 and its two-hundred day moving average is $42.41.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OMCL has been the subject of several analyst reports. Benchmark restated a "buy" rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Bank of America reduced their price target on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Wells Fargo & Company dropped their price objective on Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. reduced their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.